QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 allarity-therapeutics-q3-eps-019-beats-021-estimate

Allarity Therapeutics (NASDAQ:ALLR) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of...

 ascendiant-capital-maintains-buy-on-allarity-therapeutics-raises-price-target-to-925

Ascendiant Capital analyst Edward Woo maintains Allarity Therapeutics (NASDAQ: ALLR) with a Buy and raises the price target ...

 reported-earlier-allarity-therapeutics-enters-into-a-securities-purchase-agreement--secures-25m

-SEC Filing

 stock-market-today-nasdaq-100-futures-slip-palo-alto-xp-allarity-earnings-in-focus-updated

U.S. stock futures slipped on Monday following Friday's mixed moves. Futures of major benchmark indices were lower.

 allarity-therapeutics-q2-eps-015-beats-021-estimate

Allarity Therapeutics (NASDAQ:ALLR) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of...

 ascendiant-capital-initiates-coverage-on-allarity-therapeutics-with-buy-rating-announces-price-target-of-9

Ascendiant Capital analyst Edward Woo initiates coverage on Allarity Therapeutics (NASDAQ:ALLR) with a Buy rating and announ...

 allarity-therapeutics-patent-application-for-drp-companion-diagnostic-for-stenoparib-accepted-by-ip-australia

Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutica...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION